Drug Target Review

MAY 7, 2024

How do AI-enhanced approaches accelerate the drug development process for rare diseases? AI holds the potential to revolutionise different aspects of healthcare, particularly in the realm of clinical trials. In 2020, 78 percent of orphan drugs and biologics approved were targeted therapies.

Disease 59

Disease Clinical Trials Clinical Pharmacology Trials 59

The Pharma Data

DECEMBER 28, 2020

29, 2020 /PRNewswire/ — Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Christina Reimer as Chief Medical Officer. Her international experience in leading clinical development and in building development organizations will significantly strengthen our clinical capacity. .

Clinical Development 52

Clinical Development Doctors Drug Development International 52

The Pharma Data

DECEMBER 15, 2020

The project also seeks to engage the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to identify opportunities for regulatory endorsement of such drug development tools. The Diamyd Medical data includes relevant information about disease progression, drug effects and clinical trial design.

Drug Development 40

Drug Development Clinical Trials Trials Vaccine 40

Vial

FEBRUARY 29, 2024

Contract research organizations (CROs) are an integral partner of the drug development process, as they play a pivotal role supporting clinical trial conduct for pharmaceutical, biotechnology, and medical device sponsor companies.

Clinical Trials 52

Clinical Trials Trials Clinical Research Drug Development 52

The Pharma Data

OCTOBER 18, 2020

19, 2020 08:02 UTC. DUBLIN–( BUSINESS WIRE )– Inflection Biosciences Ltd , a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of industry veteran Gregory I. Greg possesses a wealth of experience in developing new cancer therapeutics across multiple U.S.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

DECEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain. executive vice president of research and development. “The executive vice president of research and development. “We THE WOODLANDS, Texas, Dec.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

PPD

MAY 11, 2023

The global COVID-19 pandemic increased awareness of the importance of vaccine development — both for drug developers and the public. The speed at which COVID-19 vaccines were developed was remarkable, but like most newly developed vaccines, there was variation among who could receive the shots and when.

Vaccine 52

Vaccine Clinical Trials Long-Term Care Facilities Trials 52

Vial

MARCH 1, 2024

Leading Global CROs To advance new therapies, pharma, biotech, and medical device sponsors engage CROs to help navigate the complex landscape of drug development and regulatory pathways and to manage clinical trials efficiently, ethically, and in compliance with good clinical practice ( GCP ) standards.

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

The Pharma Data

DECEMBER 13, 2020

14, 2020 10:00 UTC. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. BEIJING & CAMBRIDGE, Mass.–( He received his B.S.

Medical Schools 40

Medical Schools Clinical Development Therapies RNA 40

The Pharma Data

DECEMBER 27, 2020

28, 2020 (GLOBE NEWSWIRE) — Gritstone Oncology , Inc. The newly executed PIPE financing is subject to customary closing conditions and is expected to close on December 30, 2020, and was done in compliance with applicable Nasdaq rules and priced at the “Minimum Price” (as defined in the Nasdaq rules). and Versant Ventures.

Clinical Trials 52

Clinical Trials Compliance Clinical Development Production 52

The Pharma Data

OCTOBER 27, 2020

28, 2020 /PRNewswire/ — Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces the formation of a new Scientific Advisory Board (SAB). OSLO, Norway , Oct. Fennel cover the key scientific focus areas of Targovax.

Virus 52

Virus Engineering Clinical Development International 52

The Pharma Data

OCTOBER 25, 2020

26, 2020 11:00 UTC. We are advancing the clinical development of mRNA-1273 with our Phase 3 COVE study, which is now fully enrolled with a representative demography of participants across ages, ethnicities and high-risk populations. CAMBRIDGE, Mass.–( About Moderna.

Vaccine 52

Vaccine Clinical Development RNA Clinical Trials 52

The Pharma Data

NOVEMBER 3, 2020

04, 2020 (GLOBE NEWSWIRE) — LogicBio Therapeutics , Inc. Food and Drug Administration (FDA) has granted Fast Track designation to its clinical candidate, LB-001 for the treatment methylmalonic acidemia (MMA). LEXINGTON, Mass., Commenting on the announcement, Daniel Gruskin, M.D., About LogicBio Therapeutics.

FDA 52

FDA Treatment Clinical Trials Clinical Development 52

The Pharma Data

NOVEMBER 2, 2020

2, 2020 — An experimental antibody drug that targets one of the body’s key metabolism regulators may help obese people lose weight — at least briefly. That’s one finding from an early study that tested the injection drug, which mimics the effects of a natural hormone called fibroblast growth factor 21 (FGF21).

Drugs 52

Drugs Regulations Science Research 52

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients. “We In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4

Clinical Trials 52

Clinical Trials Small Molecule Clinical Development Disease 52

The Pharma Data

DECEMBER 28, 2020

28, 2020 /PRNewswire/ — Novotech Health Holdings (“Novotech Holdings”), the largest biotech specialist contract research organization (CRO) in Asia , today announced the appointment of Zidong Zhang as Chief Financial Officer (CFO) effective 4 January 2021. SHANGHAI and SYDNEY , Dec.

Clinical Trials 40

Clinical Trials Trials Drug Development Clinical Development 40

The Pharma Data

DECEMBER 3, 2020

4, 2020 08:00 UTC. Based on the positive Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners are confident to enter late-stage clinical development for both adjuvanted vaccines. The Phase 1 clinical trial was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 (GLOBE NEWSWIRE) — Prevail Therapeutics Inc. Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. NEW YORK, Oct. Founder and Chief Executive Officer of Prevail.

Disease 40

Disease FDA Treatment Therapies 40

The Pharma Data

JANUARY 10, 2021

Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA’s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Securities and Exchange Commission.

FDA 52

FDA Small Molecule Clinical Trials Therapies 52

The Pharma Data

JANUARY 13, 2021

As announced in January 2020, the trial met the primary endpoint of statistically significant improvement in progression-free survival (PFS), as assessed by independent review committee (IRC), in the pre-planned interim analysis. Accessed December 2020. Accessed December 2020. About Non-Small Cell Lung Cancer. v Zhang, T.,

Production 52

Production Trials Clinical Trials Treatment 52

The Pharma Data

OCTOBER 28, 2020

29, 2020 06:00 UTC. Over the past nine years, Moderna has invested in creating and developing a novel platform for designing and manufacturing a new class of mRNA-based vaccines. CAMBRIDGE, Mass.–( –( BUSINESS WIRE )– Moderna, Inc. A summary of the company’s work to date on COVID-19 can be found here.

Vaccine 40

Vaccine Government Clinical Trials RNA 40

The Pharma Data

JULY 29, 2021

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. About Eisai Co., Source link:

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

The Pharma Data

DECEMBER 9, 2020

Our lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections in hospitalized patients. JERSEY CITY, N.J.,

Hospitals 52

Hospitals Pharmacokinetics Treatment Trials 52

The Pharma Data

JANUARY 18, 2021

In-licensed from Merck KGaA, Darmstadt, Germany , atacicept has been studied previously in autoimmune diseases and shown to reduce autoantibodies in a dose-dependent fashion with once-weekly subcutaneous dosing and has a well-established and acceptable clinical safety profile.

Disease 52

Disease Science Clinical Development Treatment 52

The Pharma Data

JANUARY 27, 2021

ET ) to discuss the results and next steps in clinical development of BI-1206. Two preclinical programs in solid tumors are expected to enter clinical trials by the end of 2020. .” BioInvent will hold a key opinion leader (KOL) call today, Thursday, January 28 at 5:30 p.m. CET ( 11:30 a.m.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

Drug Target Review

SEPTEMBER 26, 2023

CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact. CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact.

Drugs 111

Drugs FDA Disease Animal Testing 111

The Pharma Data

OCTOBER 25, 2020

26, 2020 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BTI” is a clinical stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. NEW HAVEN, Conn., BioXcel Therapeutics, Inc. BioXcel Therapeutics, Inc.

Treatment 52

Treatment Trials FDA Hospitals 52

The Pharma Data

JUNE 25, 2021

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. About Eisai Co.,

Disease 40

Disease Treatment Therapies FDA 40

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), today announced that the European Patent Office (EPO) has granted Patent # 3328401 , which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology conditions. TEL AVIV, Israel, Oct.

Treatment 52

Treatment Clinical Trials Small Molecule Trials 52

LifeSciVC

JANUARY 16, 2024

In lean times such as 2023, we saw a shift towards several “hot” areas driven by massive commercial potential, clinically (± commercially) validated mechanisms, and exits that encouraged further investing, even at the early stage. Figure 2 shows pipelines across modalities for some of the competitive targets today.

Small Molecule 139

Small Molecule Trials Therapies Disease 139

The Pharma Data

JANUARY 31, 2021

Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Gilead Forward-Looking Statements.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

JUNE 26, 2021

In 2020, the trial was stopped early due to a significant improvement in OS. The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. The primary endpoints were OS and progression-free survival, and secondary endpoints included objective response rate, duration of response and quality of life. About Libtayo.

Treatment 52

Treatment Trials Disease FDA Approval 52

Agency IQ

SEPTEMBER 22, 2023

An AgencyIQ analysis from May 2020 found that a quarter of all New Molecular Entities (NMEs) approved since 2011 had relied upon a single pivotal trial, and that this reliance had remained relatively stable between 2011-2019 despite some year-to-year variability. When should this occur? at the end-of-phase 2 meeting).

FDA 40

FDA Science Trials Clinical Trials 40

The Pharma Data

OCTOBER 19, 2020

20, 2020 /PRNewswire/ — Caris Life Sciences® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Winship Cancer Institute of Emory University (Winship) has joined Caris’ Precision Oncology Alliance (The Alliance/POA). IRVING, Texas and ATLANTA , Oct.

Clinical Trials 52

Clinical Trials RNA DNA Science 52

Drug Target Review

JUNE 21, 2023

Strikingly, a strong genetic link between target and disease biology is emerging as a predictor for success in clinical trials. 2,3 This is exemplified by drugs that target disease-specific genes or genetically distinct patient subsets which are more likely to succeed in demonstrating efficacy in clinical development.

Disease 111

Disease Clinical Trials Therapies Science 111

The Pharma Data

NOVEMBER 24, 2020

24, 2020– Alnylam Pharmaceuticals, Inc. Food and Drug Administration (FDA) approved Oxlumo (lumasiran) injection for subcutaneous use, the first-ever therapy available for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. CAMBRIDGE, Mass.–(BUSINESS

FDA Approval 52

FDA Approval Treatment FDA RNA 52

The Pharma Data

OCTOBER 28, 2020

26, 2020 (GLOBE NEWSWIRE) — GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. NASDAQ: RARE), companies partnered in the development of intrathecally administered GTX-102, an investigational treatment for Angelman syndrome, today announced positive interim data from the Phase 1/2 study of GTX-102. Posted: October 2020.

Protein Expression 40

Protein Expression Therapies Treatment Production 40